KRAKOW, Poland, March 18, 2024 /PRNewswire/ -- Selvita S.A. [WSE: SLV] announced today a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio.

波兰克拉科夫，2024年3月18日/PRNewswire/--Selvita S.A.[WSE:SLV]今天宣布了一项战略举措，通过在其投资组合中增加全面的治疗性抗体发现和开发能力，显着扩大其服务组合并进入生物药物发现和开发领域。

.

.

The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped state-of-the-art laboratories.

该公司将聘请一支高度熟练的专家团队，专门从事治疗性抗体的发现和开发，并租用设备齐全的最先进实验室。

As Selvita ventures into the dynamic field of biologic drug discovery and development, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery

随着Selvita进入生物药物发现和开发的动态领域，它将提供一套全面的抗体相关服务，包括治疗性抗体发现所必需的广泛活动

Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of state-of-the-art laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering.

Selvita将在波兰弗罗茨瓦夫（Wroclaw）开设一个新的研究基地，在那里它将租用400多平方米的最先进实验室以及所有必要的基础设施。该公司还已获得进行抗体发现相关研究所需的设备。Selvita计划最初与16名经验丰富的科学家签约，这些科学家以前在Pure Biologics工作，专门从事抗体工程。

The intention of the company is to double the headcount within the next 3 years..

该公司打算在未来3年内将员工人数增加一倍。。

Milosz Gruca, PhD, Chief Commercial Officer and Executive VP at Selvita said:

Selvita首席商务官兼执行副总裁Milosz Gruca博士说：

-  We are thrilled to announce the expansion of our services portfolio with a comprehensive range of capabilities dedicated to the discovery and development of antibody-based drugs. Leveraging the state-of-the-art research infrastructure and exceptional team of scientists at our Wroclaw site, we are poised to deliver highly sought-after capabilities to our clients.

-我们很高兴地宣布，我们的服务组合将扩大，拥有一系列致力于发现和开发基于抗体的药物的综合能力。利用弗罗茨瓦夫工厂最先进的研究基础设施和杰出的科学家团队，我们准备为客户提供备受追捧的功能。

These capabilities perfectly complement Selvita's existing protein chemistry offerings. This strategic decision underscores our dedication and ambition to broaden our services portfolio beyond small molecules. Antibody discovery and development form the cornerstone of our expansion into a comprehensive suite of services for biologics drug discovery and development..

这些功能完美地补充了Selvita现有的蛋白质化学产品。这一战略决策强调了我们的奉献精神和雄心，即将我们的服务组合扩展到小分子之外。抗体的发现和开发是我们扩展到生物制剂药物发现和开发综合服务套件的基石。。

-  With biologics emerging as the fastest-growing sector within life sciences, we recognize the immense potential of this strategic move. We eagerly anticipate welcoming our new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations.

-随着生物制剂成为生命科学领域增长最快的部门，我们认识到这一战略举措的巨大潜力。我们热切期待着欢迎我们的新同事，并将弗罗茨瓦夫网站无缝整合到塞尔维塔的运营中。

More comprehensive offering and opening of new growth opportunities

提供更全面的服务并开辟新的增长机会

Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development.

进入生物药物发现和开发领域不仅标志着Selvita的重大扩张，而且为新市场和机遇铺平了道路。通过进入这一新领域，Selvita准备扩大其在小分子发现和开发方面的现有服务组合。

The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays..

生物制剂新服务的推出也将无缝补充Selvita目前在高质量重组蛋白生产领域的产品和一整套结构生物学服务，包括生产各种形式的重组抗体、抗体嵌合、双特异性抗体工程、同种型转换、，以及一系列基于单克隆抗体的检测方法。。

This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of 'All Under One Roof' Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area..

这一战略扩张使Selvita能够建立真正全面且具有竞争力的“一体化”蛋白质服务，满足其当前和潜在客户的需求和期望，并将自己定位为寻求该领域高质量服务的公司的首选合作伙伴。。

With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market.

Selvita拥有涵盖小分子和生物药物的广泛能力，能够满足不同客户的需求，并抓住快速发展的生物药物市场中的新兴机遇。

About Selvita (SLV)

关于Selvita（SLV）

Selvita is one of the leading preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

Selvita是欧洲领先的临床前合同研究组织之一，其明确的使命是：提供全面的服务，弥合早期药物发现与药物开发临床阶段之间的差距。

Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development both for small molecules and therapeutic antibodies.

Selvita提供全面的解决方案，支持客户及其药物发现项目，涵盖广泛的治疗领域，专门研究传染病、炎症、纤维化和肿瘤学。该公司提供一系列独立或完全集成的药物发现和开发解决方案，涵盖从早期药物发现到小分子和治疗性抗体的临床前开发的整个价值链。

On top of that Selvita also offers analytical support for drug development and contract testing studies..

除此之外，Selvita还为药物开发和合同测试研究提供分析支持。。

Selvita, established in 2007, operates globally with almost 900 highly qualified employees, of which over 40% hold a PhD degree. The Company's research sites are in Krakow (HQ), Poznan and Wroclaw Poland, and Zagreb, Croatia. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. .

Selvita成立于2007年，在全球运营，拥有近900名高素质员工，其中超过40%拥有博士学位。该公司的研究地点位于克拉科夫（总部）、波兰波兹南和弗罗茨瓦夫以及克罗地亚萨格勒布。国际办事处位于美国马萨诸塞州剑桥市和旧金山湾区，以及英国剑桥市。

Ardigen, a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine, is part of Selvita Group portfolio of companies. The company employs over 150 professionals.

Ardigen是一家生物信息学公司，利用先进的人工智能方法开发新型精密医学，是Selvita集团公司投资组合的一部分。该公司拥有150多名专业人员。

Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For more information, please see www.selvita.com.

Selvita在华沙证券交易所上市。有关更多信息，请访问www.selvita.com。

SOURCE Selvita S.A.

来源：Selvita美国。